Multiple endocrine neoplasia: an update

Jane E McDonnell; Matti L Gild; Roderick J Clifton-Bligh; Bruce G Robinson

doi:10.1111/imj.14394

Multiple endocrine neoplasia: an update

Intern Med J. 2019 Aug;49(8):954-961. doi: 10.1111/imj.14394.

Authors

Jane E McDonnell¹, Matti L Gild^{1

2

3}, Roderick J Clifton-Bligh^{1

2

3}, Bruce G Robinson^{1

2

3}

Affiliations

¹ Department of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, New South Wales, Australia.
² Cancer Genetics Unit, Kolling Institute, Sydney, New South Wales, Australia.
³ Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

PMID: 31387156
DOI: 10.1111/imj.14394

Abstract

The multiple endocrine neoplasia (MEN) syndromes include MEN1, MEN2 (formerly MEN2A), MEN3 (formerly MEN2B) and the recently identified MEN4. Clinical presentations are varied and often relate to the overproduction of specific hormones. Understanding the genetics of each syndrome assists in determining screening timelines. Treatments for each manifestation are dependent on location, risk of recurrence or malignancy, hormone excess and surgical morbidity. Multidisciplinary management should include geneticists, genetic counsellors, endocrinologists and endocrine surgeons.

Keywords: genetics; multiple endocrine neoplasia; screening.

Publication types

Review

MeSH terms

Combined Modality Therapy
Endocrine Surgical Procedures
Genetic Markers
Genetic Testing
Humans
Multiple Endocrine Neoplasia / classification
Multiple Endocrine Neoplasia / diagnosis*
Multiple Endocrine Neoplasia / genetics*
Multiple Endocrine Neoplasia / therapy*
Recurrence

Substances

Genetic Markers